Combined with the above results, PAAD patients in the high risk group might be more sensitive to anti-SIGLEC15 immunotherapy, but not to anti-PD-L1 and anti-CTLA4 immunotherapy. This evidence concerns the gene CD274 and pancreatic adenocarcinoma.